Inicio>>Proteins>> Growth Factors>> Macrophage Migration Inhibitory Factor>>PRGL493

PRGL493

Catalog No.GC47973

PRGL493 es un inhibidor potente y selectivo de la acil-CoA sintetasa 4 (ACSL4) de cadena larga. PRGL493 bloquea la proliferaciÓn celular y el crecimiento tumoral en modelos celulares y animales de mama y prÓstata. PRGL493 se utiliza para la investigaciÓn del cÁncer.

Products are for research use only. Not for human use. We do not sell to patients.

PRGL493 Chemical Structure

Cas No.: 2479378-45-3

Tamaño Precio Disponibilidad Cantidad
5 mg
43,00 $
Disponible
10 mg
82,00 $
Disponible
50 mg
365,00 $
Disponible
100 mg
686,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PRGL493 is an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4).1 It inhibits formation of arachidonoyl-CoA (AA-CoA) from arachidonic acid in, as well as the proliferation and migration of, PC3 and MDA-MB-231 cancer cells when used at a concentration of 50 µM. PRGL493 (5 µM) reduces production of progesterone induced by 8-Br-cyclic AMP (8-Br-cAMP) in MA-10 Leydig tumor cells. It inhibits tumor growth in a PC3 mouse xenograft model when administered at a dose of 0.25 mg/kg.

1.Castillo, A.F., Orlando, U.D., Maloberti, P.M., et al.New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesisCell. Mol. Life Sci.(2020)

Reseñas

Review for PRGL493

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PRGL493

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.